LeonaBio, Inc. is a clinical stage biopharmaceutical company focused on developing novel therapeutics for high unmet medical needs, specifically treatment resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). The company advances a pipeline of small molecule candidates that include lasofoxifene, a selective estrogen receptor modulator being evaluated in a phase 3 trial for ESR1 mutated metastatic breast cancer, and ATH 1105, a brain penetrant modulator…
LeonaBio, Inc. is a clinical stage biopharmaceutical company focused on developing novel therapeutics for high unmet medical needs, specifically treatment resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). The company advances a pipeline of small molecule candidates that include lasofoxifene, a selective estrogen receptor modulator being evaluated in a phase 3 trial for ESR1 mutated metastatic breast cancer, and ATH 1105, a brain penetrant modulator of the neurotrophic HGF system progressing toward a phase 2 study in ALS. LeonaBio leverages internal discovery and strategic in licensing to move its programs toward regulatory approval and potential commercialization.
As a pre revenue entity, LeonaBio does not yet generate product sales. Its financial resources are derived from equity financing, debt instruments and similar capital raising activities, which fund research, development, clinical trials and general corporate operations. The company anticipates future revenue from the sale of approved therapeutics and from potential licensing or partnership arrangements.
LeonaBio operates in the highly competitive biotechnology and biopharmaceutical sectors where it faces large pharmaceutical companies as well as specialized biotech firms. In oncology its lasofoxifene program competes with established endocrine therapies such as those offered by The Menarini Group (Orsedu), Eli Lilly (Inluriyo), AstraZeneca, Arvinas, Olema, and F. Hoffmann La Roche. In neuroscience ATH 1105 contends with other HGF targeted approaches like VM202 from Helixmith, and KP 100 from Kringle Pharma as well as broader ALS treatment landscapes. The company believes its differentiated mechanisms lasofoxifene’s retained activity against ESR1 mutations, and ATH 1105’s multimodal neuroprotective, anti inflammatory, and neurotrophic effects provide competitive advantages over existing standards of care.
LeonaBio intends to serve patients with advanced breast cancer and ALS and its eventual customers will include hospitals, oncology and neurology clinics, specialty pharmacies and wholesale distributors. No specific customer names are disclosed in the filing because the company’s drug candidates remain in clinical development.